Synlogic

Synlogic is a technology company.

Active

Updated: Dec 10, 2025 ·

Recent News & Mentions

May 1, 2017FundingSynlogic - Series C Feb 1, 2016FundingSynlogic - Series B Oct 1, 2014FundingSynlogic - Series A Jul 1, 2014FundingSynlogic - Series A

Financial History

Synlogic has raised $116.0M across 4 funding rounds. Most recently, it raised $42.0M Series C in May 2017.

Total Raised

$116.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Other Investors
May 1, 2017	$42.0M Series C	Atlas Venture, MPM Capital, Hakan Goker, Nest.Bio Labs, Ed Mathers, New Enterprise Associates, RA Capital, Santé Ventures
Feb 1, 2016	$40.0M Series B	Atlas Venture, MPM Capital, Hakan Goker, RA Capital
Oct 1, 2014	$5.0M Series A	Atlas Venture, MPM Capital, Hakan Goker, RA Capital
Jul 1, 2014	$29.0M Series A	Atlas Venture, MPM Capital, Hakan Goker, New Enterprise Associates, RA Capital, Santé Ventures

Financial History

Synlogic has raised $116.0M across 4 funding rounds.

Total Raised

$116.0M

Valuation

N/A

Deep Dive

High-Level Overview

Synlogic is a clinical-stage biopharmaceutical company pioneering Synthetic Biotics, living therapeutics engineered from probiotics using synthetic biology to treat serious metabolic disorders.[1][2][4] It develops oral, GI-restricted medicines that target underlying biology, with a lead program in phenylketonuria (PKU) via labafenogene marselecobac (SYNB1934) in a pivotal Phase 3 study (Synpheny-3), alongside candidates for homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria.[3] Synlogic serves patients with rare metabolic diseases underserved by current treatments, solving problems like toxic metabolite accumulation through precision genetic engineering that consumes or produces specific biological targets in the gut.[1][3] The company, headquartered in Cambridge, Massachusetts, trades as SYBX on Nasdaq with a lean team of under 25 employees and revenue below $5 million, focusing on data-driven advancement of its proprietary pipeline.[1][3]

Origin Story

Synlogic emerged from breakthroughs in synthetic biology, leveraging a reproducible, modular approach to microbial engineering for medicine.[1] Founded before its 2015 IPO (September 30), the company has evolved from early research collaborations—like with Roche on inflammatory bowel disease and Ginkgo Bioworks on preclinical assets—to clinical proof-of-concept, including plans for a PKU Phase 3 study announced around 2022.[2][3] Key milestones include 2023 financial reporting and pipeline expansion into immunology and additional metabolic indications, humanizing its mission at the "point of convergence" between human compassion and scientific logic.[2][4] While specific founders are not detailed in available data, the team's focus on nurturing talent has driven rapid progression from discovery to pivotal trials.[2]

Core Differentiators

Synlogic stands out in biotech through these key strengths:

Proprietary Synthetic Biology Platform: Uses precision genetic engineering on well-characterized probiotics to create modular, reproducible Synthetic Biotics for targeted, localized GI activity without systemic effects.[1][2][3]
Disease-Specific Pipeline: Lead assets like SYNB1934 (PKU, Phase 3) and SYNB1353 (HCU) address validated biology in rare metabolic disorders, with early-stage programs in hyperoxaluria, gout, and cystinuria.[3]
Manufacturing and Design Control: Fully designs, develops, and manufactures candidates in-house, enabling enzymatic pathways that consume/produce metabolites for novel oral therapies.[3]
Collaboration Ecosystem: Partners with leaders like Roche and Ginkgo Bioworks, blending Synlogic's drug design with external codebases for immunology and undisclosed assets.[2]

Role in the Broader Tech Landscape

Synlogic rides the synthetic biology wave, merging engineering with biology to redefine therapeutics amid rising demand for precision medicines in rare diseases.[4] Timing aligns with advances in microbial engineering and probiotics, fueled by market forces like unmet needs in metabolic disorders (e.g., PKU affects ~1 in 10,000-15,000 births) and regulatory interest in living drugs.[1][3] It influences the ecosystem by validating Synthetic Biotics as a new paradigm—potentially transformative for GI-restricted treatments—while collaborations amplify innovation, positioning it as a leader in biologics beyond traditional small molecules or gene therapies.[2][4]

Quick Take & Future Outlook

Synlogic's path forward hinges on Phase 3 success in PKU, with topline data potentially catalyzing partnerships, approvals, or acquisitions in the burgeoning synbio therapeutics market.[3] Trends like AI-driven protein design and expanded microbiome research will accelerate its pipeline, evolving its influence from niche metabolic pioneer to broader immunology player.[2] As biotech rebounds, Synlogic's lean, platform-driven model could deliver first-in-class oral biotics, bringing the transformative potential of synthetic biology to patients long underserved by conventional care.[1][4]

Sources

Frequently Asked Questions

How much funding has Synlogic raised?

Synlogic has raised $116.0M in total across 4 funding rounds.

Who are Synlogic's investors?

Synlogic's investors include Atlas Venture, MPM Capital, Hakan Goker, Nest.Bio Labs, Ed Mathers, New Enterprise Associates, RA Capital, Santé Ventures.